The Board of Directors of Sanofi India met on February 25, 2026, to approve the Audited Financial Results for the year ended December 31, 2025. Key outcomes include the recommendation of a final dividend of ₹48 per share, bringing the total dividend for 2025 to ₹123 per share (including the interim dividend). The Board also approved significant changes in directorship, including the appointment of two new directors and the resignation of one existing director.
Financial Performance for FY 2025
Sanofi India announced the approval of its Audited Financial Results for the Financial Year ended December 31, 2025. The results were prepared in accordance with Indian Accounting Standards (Ind AS) and received an unmodified audit opinion from the Statutory Auditors, Price Waterhouse & Co Chartered Accountants LLP.
Dividend Recommendation
The Board recommended a final dividend of ₹48 per equity share with a face value of ₹10 for FY 2025. This is in addition to the interim dividend of ₹75 per share declared on October 29, 2025. Consequently, the total dividend recommended for the year 2025 amounts to ₹123 per equity share.
Key Financial Summary (in Million ₹)
The audited results indicate the following key figures for the Year ended December 31, 2025, compared to the previous year:
- Total Income: ₹18,571 Million (vs. ₹20,297 Million in 2024).
- Profit After Tax (Continuing Operations): ₹3,267 Million (vs. ₹3,137 Million in 2024).
- Total Comprehensive Income: ₹3,284 Million (vs. ₹4,207 Million in 2024).
- Basic and Diluted EPS (Continuing Operations): ₹141.85 (vs. ₹136.21 in 2024).
The Net cash inflow from operating activities for 2025 stood at ₹4,383 Million, showing a slight improvement from ₹4,617 Million in 2024, after accounting for financing outflows, including a dividend payment of ₹4,422 Million.
Changes in Board of Directors
Pursuant to Regulation 30, the Board approved several changes concerning its composition, effective in early 2026.
New Appointments
- Mrs. Rajani Kesari (DIN: 02384170): Approved as an Additional and Independent Director for a 5-year term, effective April 1, 2026, subject to shareholder approval. Mrs. Kesari is a commerce graduate, Chartered Accountant, and former CFO of Nayara Energy Limited, bringing expertise in strategic planning and M&A across the Energy and Pharmaceutical sectors.
- Ms. Sudipta Chakraborty (DIN: 07166912): Approved as an Additional and Whole-time Director for a 3-year term, effective March 1, 2026. She will also be designated as a Key Managerial Personnel. Ms. Chakraborty has over two decades of legal experience, specializing in M&A, corporate governance, and compliance, having most recently served as VP-Group Legal & Compliance at Aditya Birla Group.
Resignation Noted
The Board noted the resignation of Mr. Rodolfo Hrosz (DIN: 09609832) as Non-Executive Director, effective at the close of business on February 28, 2026, due to other pre-occupations and commitments.
Key Notes from Financial Statements
The Board also reviewed significant notes accompanying the results:
- The company operates in a single business segment: ‘Pharmaceutical Business’.
- The financial results for the period starting June 1, 2024, reflect the demerger of the Consumer Healthcare business, which is now presented as discontinued operations for the year ended December 31, 2024.
- Exceptional items for 2025 related to personnel separation costs amounting to ₹273 Million.
- An incremental impact of ₹58 Million related to the implementation of the consolidated Labour Codes was recognized under Employee Benefits Expense during the year.
The Board Meeting commenced at 2:00 p.m. and concluded at 5:30 p.m. on Wednesday, February 25, 2026.
Source: BSE
